Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
PEG-MGF24 residuesYQPPSTNKNTKSQRRKGSTFEERKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: PEG-MGF, PEGylated IGF-1Ec, PEGylated MGF E-peptide
Your muscles produce Mechano Growth Factor after every hard training session, and it vanishes from circulation in about five minutes. PEG-MGF (PEGylated Mechano Growth Factor) extends that signal to an estimated 48 to 72 hours by wrapping the peptide in a polyethylene glycol chain. McKoy and colleagues confirmed that MGF's E-peptide activates human muscle progenitor cells across multiple age groups [1]. Community protocols from peptide forums report reduced DOMS and faster session-to-session recovery by weeks two to three. Dosing runs 150 to 400 mcg, injected two to three times per week post-workout. No human clinical trial has tested PEG-MGF itself; all published data covers native MGF in animal or cell models.
PEG-MGF (PEGylated Mechano Growth Factor, also called PEGylated IGF-1Ec splice variant) is a modified version of the 24-amino-acid E-peptide that your muscle tissue produces after mechanical loading. Four published references exist, and every one studied native MGF or its E-peptide fragment, not the PEGylated compound sold by research vendors. That distinction matters. Native MGF has a serum half-life of about 5 to 7 minutes. The attached PEG chain shields it from enzymatic breakdown and pushes renal filtration below the clearance threshold. The estimated half-life jumps to 48 to 72 hours, extrapolated from PEGylation pharmacokinetic principles rather than measured in a clinical study. Community use centers on muscle recovery and satellite cell priming. Users inject 150 to 400 mcg subcutaneously or intramuscularly near the trained muscle, two to three times per week after workouts. Most consistent reports describe reduced delayed-onset muscle soreness starting around week two to three. The peptide is often stacked sequentially with IGF-1 LR3, with PEG-MGF running first to expand the satellite cell pool, then IGF-1 LR3 to drive differentiation. The honest assessment: PEG-MGF sits in a category where the underlying biology is real and the community experience is cautiously positive, but the clinical evidence gap is wider than for most peptides on this platform. McKoy et al. confirmed satellite cell activation in human progenitor cells [1]. Deng et al. mapped the proliferation-without-differentiation mechanism in porcine models [2]. Goldspink's 2010 review established the theoretical framework [3]. None tested the PEGylated form.
PEG-MGF binds to receptors on muscle cells through its unique C-terminal E-peptide domain. This binding activates quiescent satellite cells through a pathway largely independent of the classical IGF-1 receptor. The E-peptide down-regulates MyoD and p21, two transcription factors that normally push satellite cells toward terminal differentiation. By suppressing these signals, PEG-MGF keeps satellite cells proliferating without committing to become mature muscle fibers. This priming phase expands the pool of myogenic precursor cells available for repair. Think of it as building inventory. Once PEG-MGF levels drop after the cycle ends, mature IGF-1 signaling through the PI3K/Akt pathway takes over. That second wave drives the expanded satellite cell pool to differentiate and fuse into existing or new muscle fibers. The PEG moiety handles the pharmacokinetic problem. Native MGF clears the bloodstream in 5 to 7 minutes because proteolytic enzymes chew through it almost immediately. The polyethylene glycol chain does two things: it creates a hydration shell that physically blocks enzyme access, and it increases the molecule's size beyond the kidney's filtration threshold. Renal clearance drops; bioactivity extends from minutes to an estimated 48 to 72 hours. Deng and colleagues mapped this proliferation-without-differentiation mechanism using porcine satellite cells [2]. The human progenitor cell work from McKoy's group [1] confirmed the activation signal crosses species. Neither study tested the PEGylated version directly.
Zero peer-reviewed studies exist for the bodybuilding PEGylated compound specifically. All evidence is extrapolated from native MGF / MGF-E peptide animal and cell studies. PEGylation pharmacokinetics (48–72h half-life) are estimated from first principles, not measured. No formal human clinical trials have been completed for PEG-MGF. Human efficacy is entirely unproven.
McKoy G et al. 2011, Mech Ageing Dev (PMID 21354439): native MGF E-peptide activates human muscle progenitor cells. Cited as most relevant positive result but studies native MGF, not PEGylated form.
No human RCTs or PK studies for PEG-MGF specifically. All 4 cited references examine native MGF or MGF-E peptide in animal/cell models. The 48–72h half-life is an estimate extrapolated from PEGylation principles. Anti-PEG antibody formation risk is undocumented for this compound but is a class risk. Body of evidence does not support any efficacy claim in humans.
Cautiously positive for recovery enhancement and DOMS reduction; skeptical for direct mass-building effects. Valued over native MGF for practical twice-weekly dosing. Commonly used as a recovery layer within GH secretagogue stacks.
Community use is based entirely on extrapolation from native MGF animal data and PEGylation pharmacokinetic principles. No human study, positive or negative, of PEGylated MGF has been published. Community reports modest recovery benefit, but no scientific evidence (positive or negative) exists for this specific compound to align or diverge from. Classified science-only to reflect that any alignment assessment is based on indirect inference, not actual data.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 150mcg | 2x/week |
| Moderate | 200mcg | 3x/week |
| Aggressive | 400mcg | 3x/week |
Reconstitution math for a 2 mg vial with 1 mL bacteriostatic water: total volume is 100 units on an insulin syringe, each unit delivers 20 mcg. So 150 mcg is 7.5 units, 200 mcg is 10 units, 400 mcg is 20 units. For a 5 mg vial with 1 mL bacteriostatic water: each unit delivers 50 mcg. That puts 150 mcg at 3 units, 200 mcg at 4 units, 400 mcg at 8 units. Start at the beginner dose (150 mcg, 2 times per week) even if you've used other peptides before. PEG-MGF has zero human dose-response data; the community arrived at these numbers by trial and error over years, not from clinical guidance. Inject post-workout, within 30 minutes of finishing your session. The satellite cell activation window overlaps with the mechanical damage signal your muscles are already producing. For bilateral muscle groups (quads, pecs), split the dose between both sides. A single-site injection for bilateral training misses half the target tissue. Don't combine PEG-MGF and IGF-1 LR3 in the same injection window. Stagger them by at least 4 to 6 hours. Both compete for satellite cell receptor binding, and concurrent dosing may negate the proliferation phase. Store reconstituted vials at 2 to 8 degrees Celsius. Use within 3 to 4 weeks. Discard if the solution turns cloudy or contains visible particles.
Cycle to prevent receptor desensitization. Most protocols use 4-8 weeks on, 2-4 weeks off. Inject on training days within 30 minutes post-workout for optimal satellite cell activation.
Community protocols cycle 4–6 weeks on / 4 weeks off based on presumed receptor accommodation within IGF-1/satellite cell pathways and to mitigate theoretical anti-PEG antibody formation risk. No human receptor desensitization data exists specifically for PEG-MGF. Cycling also limits continuous mitogenic signaling, which is prudent given the complete absence of long-term safety data in humans.
Or use the universal Peptide Calculator for any peptide.
Expected: Modest DOMS reduction and recovery improvement (anecdotal; no controlled human data). No acute anabolic effect expected at this dose.
Monitor: Check blood glucose at baseline and day 7. Inspect injection sites before each use.
Gather supplies: PEG-MGF vial (2 mg or 5 mg lyophilized), bacteriostatic water, alcohol swabs, 29 to 31 gauge insulin syringe (0.5 mL or 1 mL).
Reconstitute by adding 1 mL of bacteriostatic water to the vial. Direct the stream against the glass wall, not onto the powder. Swirl gently until dissolved. Do not shake. For a 2 mg vial, this gives 20 mcg per unit. For a 5 mg vial, 50 mcg per unit.
Using a 2 mg vial with 1 mL BAC water: beginner 150 mcg = 7.5 units, moderate 200 mcg = 10 units, aggressive 400 mcg = 20 units. Using a 5 mg vial: 150 mcg = 3 units, 200 mcg = 4 units, 400 mcg = 8 units.
For subcutaneous injection, pinch a fold of skin on the abdomen or outer thigh and insert at a 45 degree angle. For intramuscular injection near the trained muscle, insert at a 90 degree angle into the target area.
For bilateral muscle groups, split the dose between both sides (e.g., 100 mcg per quad for a 200 mcg dose).
Timing is post-workout, within 30 minutes of finishing your session. Inject on training days only, 2 to 3 times per week depending on your dosing tier.
Store the reconstituted vial in the refrigerator at 2 to 8 degrees Celsius. Use within 3 to 4 weeks. Lyophilized (unreconstituted) vials store at 2 to 8 degrees Celsius for up to 12 months, or at minus 20 degrees Celsius for longer-term storage.
Standard community dose 150–400 mcg per injection
IM injection near the trained muscle maximizes potential satellite cell exposure at the site of mechanical damage. Split dose bilaterally for paired muscle groups (quads, pecs, biceps). Unlike native MGF, the 48–72h half-life allows some systemic distribution even from IM dosing.
Same dose range; site-specific localized effect may be reduced vs IM
The extended half-life makes SC dosing significantly more practical than for native MGF: systemic PEG-MGF exposure and satellite cell activation occurs. Community commonly uses SC abdominal injection. Localized muscle-specific effect is likely reduced vs IM, but systemic satellite cell priming still occurs.
PEG-MGF drives satellite cell proliferation without differentiation; IGF-1 LR3 drives the full PI3K/Akt/mTOR differentiation cascade. Sequential use covers both phases of muscle regeneration.
PEG-MGF 200–400 mcg 3×/week post-workout × 4–6 weeks → switch to IGF-1 LR3 50–100 mcg once daily × 4 weeks. Stagger by ≥4–6h if used on same training days: do NOT co-administer in the same injection window.
BPC-157 addresses connective tissue, gut, and systemic healing via nitric oxide pathways. PEG-MGF targets satellite cell activation. Combined for injury recovery protocols: complementary mechanisms with no documented interaction.
BPC-157 250–500 mcg/day SC + PEG-MGF 200 mcg 2–3×/week post-workout × 4–6 weeks
TB-500 promotes actin dynamics, angiogenesis, and progenitor cell migration systemically. PEG-MGF activates muscle satellite cells locally. Combined for injury recovery and muscle repair.
TB-500 2–5 mg SC 2×/week + PEG-MGF 200 mcg 2–3×/week post-workout × 4–6 weeks
Ipamorelin stimulates pulsatile GH release upstream; PEG-MGF acts downstream at the satellite cell level. Community uses GH secretagogues as a foundation with PEG-MGF to maximize the muscle repair and growth environment.
Ipamorelin 200–300 mcg SC 3×/day + PEG-MGF 200 mcg post-workout 3×/week; ipamorelin continues through PEG-MGF on and off phases.
Simultaneous dosing in the same injection window may cause receptor competition at the satellite cell level. Separate by ≥4–6 hours or run in alternating cycles. Sequential use is a validated community stack: this is a timing precaution, not an absolute contraindication.
PEG-MGF carries an independent hypoglycemia risk via IGF-1 pathway activation. Combining with exogenous insulin or insulin secretagogues produces additive glucose-lowering effects. Avoid co-administration unless under medical supervision with active glucose monitoring.
Do not combineGlucocorticoids impair satellite cell activation and antagonize myogenic pathways, significantly reducing expected PEG-MGF benefit.
Pricing updated 2026-04-09
The biggest concern with PEG-MGF is the complete absence of human safety data. No clinical trial, no pharmacokinetic study, and no toxicology profile has been conducted on this specific compound in humans. Every safety assessment is borrowed from native MGF animal research, PEGylation class effects, and community self-reports. That isn't a reason to panic, but it means you're working without guardrails that exist for better-studied peptides. Cancer risk deserves attention first. PEG-MGF activates satellite cell proliferation through IGF-1 pathway signaling. Any compound that stimulates cell division carries a theoretical mitogenic risk. The peptide is contraindicated for anyone with active malignancy, a history of cancer, or pre-existing musculoskeletal tumors. This isn't a soft warning. Hypoglycemia is the most commonly reported acute side effect at higher doses. PEG-MGF activates the IGF-1 pathway, which has independent glucose-lowering activity. Symptoms include shakiness, sweating, and post-injection fatigue. This risk compounds when stacking with IGF-1 LR3 or exogenous insulin. Monitor fasting blood glucose at baseline, at day 7, and at the end of each cycle. Injection site reactions (pain, redness, swelling) are standard for a peptide administered subcutaneously or intramuscularly. These tend to be worse during the first week and settle as technique improves and sites are rotated. Water retention and joint discomfort show up in community reports, typically at moderate-to-aggressive doses. Localized muscle tightness or cramping near the injection site is reported during the first two weeks. Blood pressure changes appear occasionally but without a clear pattern. Anti-PEG antibody formation is the long-term unknown. Other PEGylated drugs, including pegfilgrastim and PEGylated asparaginase, have triggered anti-PEG immune responses in clinical use. Nobody has studied this for PEG-MGF specifically. Worsening injection site reactions across successive cycles, rather than improving tolerance, may signal antibody formation. Cycling off for four or more weeks between courses is the community's precautionary approach. Contraindications: active malignancy or cancer history, pregnancy or breastfeeding (zero safety data), active intracranial lesions or pituitary tumors, uncontrolled diabetes or severe hypoglycemia risk, severe hepatic or renal impairment, known hypersensitivity to PEGylated compounds, pre-existing musculoskeletal tumors. Stop immediately and seek medical attention if you experience signs of hypoglycemia, infection at the injection site, or worsening reactions across cycles.
Verify PEG-MGF dosing and safety with a second opinion
Research-grade only: no pharmaceutical manufacturing standards apply. PEGylation adds complexity; confirming intact PEG-peptide conjugation requires mass spectrometry beyond basic HPLC purity testing. No regulatory oversight. Community reports inconsistent purity across vendors. Anti-PEG immune response risk is elevated with lower-purity batches containing free PEG fragments.
| Test | When | Target |
|---|---|---|
| Fasting blood glucose | Baseline before starting; recheck at day 7 and end of each cycle | 70–100 mg/dL fasting |
| Injection site inspection | Before each injection session | — |
| Serum IGF-1 | Optional: baseline and end of cycle: particularly if stacking with IGF-1 LR3 or GH secretagogues | Age-adjusted normal range (typically 115–307 ng/mL for adults) |
PEG-MGF activates the IGF-1 pathway and carries an independent hypoglycemia risk, especially at higher doses or when stacked with other IGF pathway peptides.
Repeated SC or IM injections risk infection, granuloma, nodule formation, or abscess: particularly with IM site-specific protocols.
Compound IGF-1 pathway stimulation from PEG-MGF + IGF-1 LR3 + GH secretagogue can compound pathway exposure beyond expected single-agent levels.
Satellite cell activation begins. Mild injection site reactions may occur. Improved subjective recovery from workouts reported by some users. No visible changes yet.
Noticeable reduction in delayed-onset muscle soreness (DOMS). Training capacity may increase as recovery improves. Early gains in muscle fullness reported.
Peak effects on muscle repair and growth become apparent. Measurable improvements in recovery time between sessions. Increased muscle density and hardness reported.
Receptor sensitivity reset period. Satellite cell pool remains expanded from the on-cycle priming. Maintain training stimulus to retain gains. Transition to other peptides if desired.
Days 1 to 7 (Injection Site Adaptation): No measurable anabolic changes during this phase. PEG-MGF begins reaching satellite cells, but proliferation takes days to initiate at the cellular level. Expect mild injection site redness and swelling, especially if you're new to intramuscular or subcutaneous peptide injections. Some users report a subtle reduction in post-workout fatigue by day 5 to 7, though this is difficult to separate from placebo at such an early stage. Weeks 2 to 3 (Recovery Improvement Window): This is the most consistent benefit period based on community reports. DOMS drops noticeably, and session-to-session recovery feels faster. Training frequency often increases because soreness no longer forces extra rest days. Animal models show satellite cell activation peaking around 24 to 72 hours after mechanical stimulus [1]; PEG-MGF's extended half-life would maintain that activation signal continuously between doses. Localized muscle tightness or fullness at injection sites is common. Some users report mild joint stiffness. Weeks 4 to 6 (Peak Satellite Cell Priming): Increased muscle fullness and density are reported during this window. Extrapolating from animal data, the satellite cell pool should be meaningfully expanded by this phase. Recovery benefits may plateau or show diminishing returns past week 4. That pattern is consistent with receptor accommodation or early anti-PEG antibody formation. If effects fade noticeably before week 6, extending the upcoming off-cycle to 6 or more weeks is worth considering. Off-cycle, Weeks 7 and Beyond (Receptor Reset and Gain Retention): The expanded satellite cell pool persists after PEG-MGF clears. Continued training converts those progenitor cells into new myonuclei, the permanent markers of muscle adaptation. No human data on withdrawal effects or rebound exists. Community users who transition into an IGF-1 LR3 phase (50 to 100 mcg daily for 4 weeks) after PEG-MGF report better gain retention than PEG-MGF alone. Maintain training stimulus and adequate protein intake (1.8 g/kg/day minimum) to retain what the cycle built.
No measurable anabolic changes. PEG-MGF begins reaching satellite cells, but proliferation takes days to initiate.
Mild injection site redness and swelling common for first-time users. Some report subjective fatigue reduction by day 5–7.
No human clinical timeline data. Animal models show satellite cell activation peaking ~24–72h post-mechanical stimulus; PEG-MGF's 48–72h half-life would maintain this signal continuously.
Most consistent benefit period: DOMS noticeably reduced, session-to-session recovery faster. Anecdotal improvement in training frequency.
No human clinical endpoint data. Extrapolating from animal models: satellite cell pool should be meaningfully expanded by this phase.
Increased muscle fullness and density reported. Recovery benefit may plateau. Some users note diminishing returns past week 4: consistent with receptor accommodation or antibody formation.
Receptor sensitivity normalization period. Satellite cell pool remains expanded; training converts expanded pool into new myonuclei. No human withdrawal or rebound data.
Benefits largely maintained with continued training stimulus and adequate nutrition. Sequential IGF-1 LR3 users report better retention than PEG-MGF alone.
Source: Estimated from PEGylation pharmacokinetic principles; native MGF t1/2 ~5-7 min, PEGylated form ~48-72 hours. No direct human PK study available.
Loading the interactive decay curve.
PEG-MGF has no FDA approval for any indication. It carries a research-only regulatory status. No clinical trial has been registered for this compound, and no pharmaceutical manufacturer produces it under GMP conditions. The peptide is sold by research vendors labeled "for research purposes only" or "not for human consumption." Quality control is a particular concern with PEG-MGF. Confirming intact PEGylation requires mass spectrometry beyond standard HPLC purity testing. Community reports flag inconsistent purity across vendors. Request lot-specific third-party certificates of analysis with both HPLC and mass spectrometry results. No compounding pharmacy protocols exist for PEG-MGF. It is not available through any regulated pharmacy channel. Athletes subject to drug testing should treat this as prohibited. WADA lists peptide hormones and growth factors as a banned category. PEG-MGF falls squarely within that classification. This content is for educational and informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any peptide.
Peptide Schedule Research TeamReviewed Apr 20264 Citations
